Clinical characteristics of patients with and without detection of the FLT3/ITD mutation in CD34+/CD33- progenitor cells
. | Without FLT3/ITD . | With FLT3/ITD . | P . |
|---|---|---|---|
| Total, n (%) | 5 (21) | 19 (79) | |
| Median age, y (range) | 16.3 (8.9-19.8) | 14.3 (3.0-18.7) | .57 |
| Sex | |||
| Male, n (%) | 2 (40) | 12 (63) | .615 |
| Female, n (%) | 3 (60) | 7 (37) | |
| Median WBC count, × 109/L (range) | 64.1 (5.6-250.3) | 42.1 (1.6-860) | .943 |
| Median marrow blast, % (range) | 81 (36-96) | 74 (44-93) | .776 |
| Median CD34+/CD33- cell count, × 104 (range) | 0.2 (0.05-32) | 3.3 (0.08-150) | .075 |
| Allelic ratio | |||
| No more than 0.4, n (%) | 4 (67) | 3 (16) | .015 |
| More than 0.4, n (%) | 1 (33) | 16 (84) | |
| Postinduction therapy | |||
| Allo BMT, n (%) | 2 (40) | 3 (30) | .99 |
| Chemo, n (%) | 3 (60) | 7 (70) | |
| Induction outcome | |||
| CR/PR, n (%) | 5/0 (100) | 9/1 (53) | .118 |
| Fail, n (%) | 0 (0) | 4 (21) | .544 |
| Death, n (%) | 0 (0) | 5 (26) | .544 |
. | Without FLT3/ITD . | With FLT3/ITD . | P . |
|---|---|---|---|
| Total, n (%) | 5 (21) | 19 (79) | |
| Median age, y (range) | 16.3 (8.9-19.8) | 14.3 (3.0-18.7) | .57 |
| Sex | |||
| Male, n (%) | 2 (40) | 12 (63) | .615 |
| Female, n (%) | 3 (60) | 7 (37) | |
| Median WBC count, × 109/L (range) | 64.1 (5.6-250.3) | 42.1 (1.6-860) | .943 |
| Median marrow blast, % (range) | 81 (36-96) | 74 (44-93) | .776 |
| Median CD34+/CD33- cell count, × 104 (range) | 0.2 (0.05-32) | 3.3 (0.08-150) | .075 |
| Allelic ratio | |||
| No more than 0.4, n (%) | 4 (67) | 3 (16) | .015 |
| More than 0.4, n (%) | 1 (33) | 16 (84) | |
| Postinduction therapy | |||
| Allo BMT, n (%) | 2 (40) | 3 (30) | .99 |
| Chemo, n (%) | 3 (60) | 7 (70) | |
| Induction outcome | |||
| CR/PR, n (%) | 5/0 (100) | 9/1 (53) | .118 |
| Fail, n (%) | 0 (0) | 4 (21) | .544 |
| Death, n (%) | 0 (0) | 5 (26) | .544 |
Allo indicates allogeneic hematopoietic cell transplantation; BMT, bone marrow transplantation; chemo, chemotherapy